{"title":"代谢综合征与长效注射抗精神病药物的关系:系统综述","authors":"TTK Nguyen , C McDonald , B Hallahan","doi":"10.1016/j.ejpsy.2022.01.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and Objectives</h3><p>Long-acting injectable (LAI) antipsychotics<span><span> increase patient adherence, reduce relapse rates and facilitate regular interaction with community mental health teams. Antipsychotics are however associated with adverse effects including </span>metabolic syndrome<span>. This review outlines the rates of monitoring for and rates of metabolic syndrome in patients treated with LAI antipsychotics.</span></span></p></div><div><h3>Methods</h3><p>We searched Medline, EMBASE, and Cochrane for Medical Subject Heading (MeSH) terms including metabolic syndrome or MetS and depot or LAI antipsychotics. We included data regarding participants’ clinical characteristics, dose and type of antipsychotics administered, rates of monitoring for- and rates of metabolic syndrome and individual metabolic parameters (body mass index or measure of central obesity, blood pressure, lipid levels, plasma glucose and/or HbA1C levels).</p></div><div><h3>Results</h3><p><span>Six studies were included that evaluated rates of monitoring for- and 39 studies examined rates of metabolic syndrome or individual metabolic parameters. Metabolic parameters were not routinely measured in approximately 75% of patients. Rates of metabolic syndrome ranged between 24.3% and 53.2%, with most studies finding no significant differences between oral and LAIs; however, a more preferable weight and lipid profile was detected with LAIs compared to the oral antipsychotics olanzapine and </span>clozapine. Rates of metabolic syndrome and abnormalities of metabolic parameters were comparable among first- and second-generation and between second-generation LAIs.</p></div><div><h3>Conclusions</h3><p>LAI antipsychotics are associated with high rates of metabolic syndrome but low rates of regular monitoring. A robust screening plan to monitor for metabolic syndrome in individuals treated with LAIs is advised including measurement of individual metabolic parameters.</p></div>","PeriodicalId":12045,"journal":{"name":"European Journal of Psychiatry","volume":"36 3","pages":"Pages 163-175"},"PeriodicalIF":2.5000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"The association of metabolic syndrome and long acting injectable antipsychotics: A systematic review\",\"authors\":\"TTK Nguyen , C McDonald , B Hallahan\",\"doi\":\"10.1016/j.ejpsy.2022.01.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background and Objectives</h3><p>Long-acting injectable (LAI) antipsychotics<span><span> increase patient adherence, reduce relapse rates and facilitate regular interaction with community mental health teams. Antipsychotics are however associated with adverse effects including </span>metabolic syndrome<span>. This review outlines the rates of monitoring for and rates of metabolic syndrome in patients treated with LAI antipsychotics.</span></span></p></div><div><h3>Methods</h3><p>We searched Medline, EMBASE, and Cochrane for Medical Subject Heading (MeSH) terms including metabolic syndrome or MetS and depot or LAI antipsychotics. We included data regarding participants’ clinical characteristics, dose and type of antipsychotics administered, rates of monitoring for- and rates of metabolic syndrome and individual metabolic parameters (body mass index or measure of central obesity, blood pressure, lipid levels, plasma glucose and/or HbA1C levels).</p></div><div><h3>Results</h3><p><span>Six studies were included that evaluated rates of monitoring for- and 39 studies examined rates of metabolic syndrome or individual metabolic parameters. Metabolic parameters were not routinely measured in approximately 75% of patients. Rates of metabolic syndrome ranged between 24.3% and 53.2%, with most studies finding no significant differences between oral and LAIs; however, a more preferable weight and lipid profile was detected with LAIs compared to the oral antipsychotics olanzapine and </span>clozapine. Rates of metabolic syndrome and abnormalities of metabolic parameters were comparable among first- and second-generation and between second-generation LAIs.</p></div><div><h3>Conclusions</h3><p>LAI antipsychotics are associated with high rates of metabolic syndrome but low rates of regular monitoring. A robust screening plan to monitor for metabolic syndrome in individuals treated with LAIs is advised including measurement of individual metabolic parameters.</p></div>\",\"PeriodicalId\":12045,\"journal\":{\"name\":\"European Journal of Psychiatry\",\"volume\":\"36 3\",\"pages\":\"Pages 163-175\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2022-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0213616322000027\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0213616322000027","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
The association of metabolic syndrome and long acting injectable antipsychotics: A systematic review
Background and Objectives
Long-acting injectable (LAI) antipsychotics increase patient adherence, reduce relapse rates and facilitate regular interaction with community mental health teams. Antipsychotics are however associated with adverse effects including metabolic syndrome. This review outlines the rates of monitoring for and rates of metabolic syndrome in patients treated with LAI antipsychotics.
Methods
We searched Medline, EMBASE, and Cochrane for Medical Subject Heading (MeSH) terms including metabolic syndrome or MetS and depot or LAI antipsychotics. We included data regarding participants’ clinical characteristics, dose and type of antipsychotics administered, rates of monitoring for- and rates of metabolic syndrome and individual metabolic parameters (body mass index or measure of central obesity, blood pressure, lipid levels, plasma glucose and/or HbA1C levels).
Results
Six studies were included that evaluated rates of monitoring for- and 39 studies examined rates of metabolic syndrome or individual metabolic parameters. Metabolic parameters were not routinely measured in approximately 75% of patients. Rates of metabolic syndrome ranged between 24.3% and 53.2%, with most studies finding no significant differences between oral and LAIs; however, a more preferable weight and lipid profile was detected with LAIs compared to the oral antipsychotics olanzapine and clozapine. Rates of metabolic syndrome and abnormalities of metabolic parameters were comparable among first- and second-generation and between second-generation LAIs.
Conclusions
LAI antipsychotics are associated with high rates of metabolic syndrome but low rates of regular monitoring. A robust screening plan to monitor for metabolic syndrome in individuals treated with LAIs is advised including measurement of individual metabolic parameters.
期刊介绍:
The European journal of psychiatry is a quarterly publication founded in 1986 and directed by Professor Seva until his death in 2004. It was originally intended to report “the scientific activity of European psychiatrists” and “to bring about a greater degree of communication” among them. However, “since scientific knowledge has no geographical or cultural boundaries, is open to contributions from all over the world”. These principles are maintained in the new stage of the journal, now expanded with the help of an American editor.